Oncoinvent Announces Promising 18-Month Trial Results for Radspherin®
Oncoinvent ASA, a leading clinical-stage radiopharmaceutical company, has recently shared the results from its ongoing research on Radspherin®, an innovative treatment aimed at fighting solid cancers. The findings from the 18-month follow-up of their Phase 1 clinical trial, specifically focused on patients with recurrent ovarian cancer, show compelling outcomes that highlight the potential of Radspherin® in improving patient care.
Understanding the Trial Details and Patient Outcomes
The ongoing trial (RAD-18-001) enrolled 10 patients who received a single dose of 7 MBq of Radspherin®. Remarkably, at the 12-month review, only 1 patient had shown signs of disease recurrence, representing a mere 10% recurrence rate. This outcome stands in stark contrast to similar patient groups treated with standard care, where approximately 40% typically experience recurrence at this stage.
Impact on Patient Lives and Future Research
Dr. Luis Chiva, a Principal Investigator and Director at Clinica Universidad de Navarra, expressed confidence in the findings. He stated that ovarian cancer remains a challenging area, with many patients facing severe recurrences despite comprehensive treatment plans. The outcomes from Radspherin® could mean a new hope for many, possibly extending their lives and improving the quality of care they receive.
Advancing to Phase 2 Trials
Øystein Soug, the CEO of Oncoinvent, emphasized the significance of these results in confirming the effectiveness of Radspherin®. Due to the encouraging data, the company is enthusiastic about advancing to the next stages of clinical trials, which will evaluate the efficacy of Radspherin® in improving progression-free survival for patients battling peritoneal metastasis from ovarian cancer.
Future Updates and Company Operations
In light of these promising results, Oncoinvent is set to provide further insights into its operations and the forthcoming Phase 2 trial during a scheduled Quarterly Update in late April. This reflects their commitment to transparency and collaboration with stakeholders and the wider medical community.
About Oncoinvent and Radspherin®
Oncoinvent specializes in creating next-generation cancer therapies using modern radiopharmaceuticals. Their flagship product, Radspherin®, utilizes radium-224 to target micro-metastases post-surgery directly. This innovative approach aims to harness the benefits of radiopharmaceuticals while minimizing the complications associated with different biological therapies. Currently, they are engaged in critical trials in various regions, including the US, UK, and Europe, and are optimistic about the safety and efficacy of their treatment.
Defining the Mechanism of Radspherin®
The mechanism behind Radspherin® lies in its capacity to release alpha-particles through the decay of radium-224, delivering highly precise radiation to cancerous cells in body cavities. This unique delivery system is under investigation specifically for treating peritoneal carcinomatosis stemming from both ovarian and colorectal cancer. Administered intraperitoneally after surgical tumor removal, Radspherin® represents a promising avenue in cancer treatment protocols.
Frequently Asked Questions
What are Radspherin®'s current clinical trial results?
The recent Phase 1 trial showed that only 10% of patients experienced cancer recurrence within 18 months, which is significantly lower than the expected rate.
How does Radspherin® work?
Radspherin® employs alpha-emitting radium-224 to target and treat cancer cells in body cavities, allowing for effective localized treatment.
What does the future hold for Oncoinvent?
Oncoinvent plans to initiate Phase 2 trials based on the positive results observed in the Phase 1 trial, continuing to explore Radspherin®’s potential.
Where is Oncoinvent headquartered?
Oncoinvent is based in Oslo, Norway, and operates a state-of-the-art facility for the production of their drug products.
Who can I contact for more information about Oncoinvent?
For further inquiries, you can reach out directly to Øystein Soug, the CEO of Oncoinvent.
